In this issue:
Geospatial disparities in curable breast cancer treatment in the US
Early local therapy for the primary site in de novo stage IV breast cancer
Sapanisertib + fulvestrant for progressive oestrogen receptor+/HER2– advanced breast cancer
Adding carboplatin ±veliparib to standard neoadjuvant chemotherapy in TNBC
Ribociclib + letrozole for hormone receptor+/HER2– advanced breast cancer: subgroups of interest
Palbociclib + fulvestrant for advanced breast cancer in the real world
BMI does not affect aromatase inhibitor efficacy in metastatic breast cancer
Afatinib ±vinorelbine or paclitaxel in HER2+ breast cancer after failure/progression with trastuzumab and/or lapatinib
Trastuzumab biosimilar combined with pertuzumab in HER2+ early breast cancer
Preoperative axillary nodal staging of invasive lobular breast cancer
Please login below to download this issue (PDF)